Galapagos NV (GLPG)’s Financial Results Comparing With Aridis Pharmaceuticals Inc. (NASDAQ:ARDS)

Both Galapagos NV (NASDAQ:GLPG) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galapagos NV N/A 0.00 N/A -1.69 0.00
Aridis Pharmaceuticals Inc. 2.16M 33.73 23.74M -2.98 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Galapagos NV and Aridis Pharmaceuticals Inc.

Profitability

Table 2 provides us Galapagos NV and Aridis Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Galapagos NV 0.00% 0% 0%
Aridis Pharmaceuticals Inc. -1,099.07% 54.6% -91.5%

Analyst Recommendations

The following table given below contains the ratings and recommendations for Galapagos NV and Aridis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Galapagos NV 0 0 6 3.00
Aridis Pharmaceuticals Inc. 0 0 0 0.00

The upside potential is 23.70% for Galapagos NV with consensus price target of $126.5.

Institutional & Insider Ownership

Galapagos NV and Aridis Pharmaceuticals Inc. has shares held by institutional investors as follows: 19.34% and 0.7%. Competitively, insiders own roughly 17.8% of Aridis Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Galapagos NV 1.58% -6.19% 5.07% 0.46% 20.27% 9.12%
Aridis Pharmaceuticals Inc. -25% -34.84% -41.67% 0% 0% -38.85%

For the past year Galapagos NV has 9.12% stronger performance while Aridis Pharmaceuticals Inc. has -38.85% weaker performance.

Summary

On 6 of the 10 factors Galapagos NV beats Aridis Pharmaceuticals Inc.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.